- Home
- IDAI vs CELU Comparison
IDAI vs CELU Comparison
Compare IDAI & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IDAI | CELU |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9M | 17.3M |
| IPO Year | 2022 | 2019 |
Fundamental Metrics
Financial Performance| Metric | IDAI | CELU |
|---|---|---|
| Price | $2.72 | $1.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 34.3K | ★ 114.6K |
| Earning Date | 11-13-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 76.50 | N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | ★ $26,550,000.00 |
| Revenue This Year | $59.48 | $165.42 |
| Revenue Next Year | $199.81 | $305.36 |
| P/E Ratio | ★ N/A | $26.13 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.17 | $0.56 |
| 52 Week High | $5.28 | $2.55 |
Technical Indicators
Market Signals| Indicator | IDAI | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 42.29 | 35.76 |
| Support Level | $2.31 | $0.63 |
| Resistance Level | $2.80 | $1.43 |
| Average True Range (ATR) | 0.25 | 0.14 |
| MACD | -0.05 | -0.06 |
| Stochastic Oscillator | 15.38 | 5.73 |
Price Performance
Historical ComparisonAbout IDAI T Stamp Inc.
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The company operates in one reportable segment, artificial intelligence-powered solutions. The artificial intelligence-powered solutions segment generates revenue from software licenses, professional services, and recurring SaaS revenue.
About CELU Celularity Inc.
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.